About Progenics Pharmaceuticals (NASDAQ:PGNX)
Progenics Pharmaceuticals, Inc. is engaged in developing medicines and other products for targeting and treating cancer. The Company's pipeline includes therapeutic agents designed to target cancer (AZEDRA and 1095); prostate specific membrane antigen (PSMA)-targeted imaging agents for prostate cancer (1404 and PyL), and imaging analysis tools. It also includes commercial product, RELISTOR (methylnaltrexone bromide) for opioid-induced constipation. AZEDRA is a radiotherapeutic product candidate in development as a treatment for malignant and/or recurrent pheochromocytoma and paraganglioma, rare tumors found in the adrenal glands and outside of the adrenal glands, respectively. RELISTOR is a treatment for opioid induced constipation. PyL is a clinical-stage, fluorinated PSMA-targeted Positron Emission Topography (PET) imaging agent for prostate cancer. PSMA TTC is a thorium-227 labeled PSMA-targeted antibody therapeutic.
Industry, Sector and Symbol
Trailing P/E Ratio-10.3286256352653
Forward P/E Ratio-11.25
Sales & Book Value
Annual Sales$11.70 million
Price / Sales46.83
Price / CashN/A
Book Value$0.90 per share
Price / Book8.38
Return on Equity-87.30%
Return on Assets-38.46%
Progenics Pharmaceuticals (NASDAQ:PGNX) Frequently Asked Questions
What is Progenics Pharmaceuticals' stock symbol?
Progenics Pharmaceuticals trades on the NASDAQ under the ticker symbol "PGNX."
How were Progenics Pharmaceuticals' earnings last quarter?
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) announced its quarterly earnings results on Thursday, March, 8th. The biotechnology company reported ($0.21) earnings per share (EPS) for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.21). The biotechnology company had revenue of $3.90 million for the quarter, compared to analyst estimates of $3.18 million. Progenics Pharmaceuticals had a negative net margin of 436.08% and a negative return on equity of 87.30%. The business's revenue for the quarter was down 15.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.10) EPS. View Progenics Pharmaceuticals' Earnings History.
When will Progenics Pharmaceuticals make its next earnings announcement?
Where is Progenics Pharmaceuticals' stock going? Where will Progenics Pharmaceuticals' stock price be in 2018?
4 brokerages have issued twelve-month price objectives for Progenics Pharmaceuticals' shares. Their forecasts range from $12.00 to $15.00. On average, they expect Progenics Pharmaceuticals' stock price to reach $13.75 in the next year. View Analyst Ratings for Progenics Pharmaceuticals.
What are Wall Street analysts saying about Progenics Pharmaceuticals stock?
Here are some recent quotes from research analysts about Progenics Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics' first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc. " (3/14/2018)
- 2. Cantor Fitzgerald analysts commented, "PGNX has completed the rolling NDA for AZEDRA for pheochromocytoma and paraganglioma." (11/2/2017)
Who are some of Progenics Pharmaceuticals' key competitors?
Some companies that are related to Progenics Pharmaceuticals include Apellis Pharmaceuticals (APLS), Assembly Biosciences (ASMB), Myovant Sciences (MYOV), Cellectis (CLLS), Dynavax Technologies (DVAX), DBV Technologies (DBVT), Wave Life Sciences (WVE), Revance Therapeutics (RVNC), Genomic Health (GHDX), ARMO BioSciences (ARMO), Acorda Therapeutics (ACOR), Audentes Therapeutics (BOLD), TherapeuticsMD (TXMD), Adaptimmune Therapeutics (ADAP), Bavarian Nordic (BVNRY), Athenex (ATNX), Zai Lab (ZLAB) and Biohaven Pharmaceutical (BHVN).
Who are Progenics Pharmaceuticals' key executives?
Progenics Pharmaceuticals' management team includes the folowing people:
- Peter J. Crowley, Independent Chairman of the Board (Age 59)
- Mark R. Baker J.D., , Chief Executive Officer, Director (Age 62)
- Patrick Fabbio, Chief Financial Officer, Senior Vice President (Age 49)
- Vivien Wong Ph.D., Executive Vice President - Development (Age 60)
- Jeffrey D. Summer, Senior Vice President - Strategy and Performance (Age 57)
- Bryce Tenbarge, Vice President - Commercial (Age 44)
- Bradley L. Campbell, Independent Director (Age 41)
- Karen Jean Ferrante M.D., Independent Director (Age 59)
- Michael D. Kishbauch, Independent Director (Age 68)
- David A. Scheinberg MD., Ph.D., Independent Director (Age 61)
Has Progenics Pharmaceuticals been receiving favorable news coverage?
News articles about PGNX stock have been trending positive recently, Accern Sentiment reports. The research group scores the sentiment of press coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Progenics Pharmaceuticals earned a daily sentiment score of 0.28 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 46.19 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the next several days.
Who are Progenics Pharmaceuticals' major shareholders?
Progenics Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (14.23%), Carillon Tower Advisers Inc. (5.21%), Pinnacle Associates Ltd. (3.15%), Ardsley Advisory Partners (2.60%), Phocas Financial Corp. (2.05%) and Rice Hall James & Associates LLC (1.97%). View Institutional Ownership Trends for Progenics Pharmaceuticals.
Which institutional investors are selling Progenics Pharmaceuticals stock?
PGNX stock was sold by a variety of institutional investors in the last quarter, including Deutsche Bank AG, Pinnacle Associates Ltd., TIAA CREF Investment Management LLC, Fuller & Thaler Asset Management Inc., Ardsley Advisory Partners, Royce & Associates LP, Phocas Financial Corp. and Bank of New York Mellon Corp. View Insider Buying and Selling for Progenics Pharmaceuticals.
Which institutional investors are buying Progenics Pharmaceuticals stock?
PGNX stock was bought by a variety of institutional investors in the last quarter, including Carillon Tower Advisers Inc., BlackRock Inc., Landscape Capital Management L.L.C., Arizona State Retirement System, Rice Hall James & Associates LLC, Perceptive Advisors LLC, Fisher Asset Management LLC and Creative Planning. View Insider Buying and Selling for Progenics Pharmaceuticals.
How do I buy shares of Progenics Pharmaceuticals?
Shares of PGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Progenics Pharmaceuticals' stock price today?
One share of PGNX stock can currently be purchased for approximately $7.54.
How big of a company is Progenics Pharmaceuticals?
Progenics Pharmaceuticals has a market capitalization of $607.45 million and generates $11.70 million in revenue each year. The biotechnology company earns $-51,010,000.00 in net income (profit) each year or ($0.73) on an earnings per share basis. Progenics Pharmaceuticals employs 64 workers across the globe.
How can I contact Progenics Pharmaceuticals?
Progenics Pharmaceuticals' mailing address is 285 FULTON STREET 47TH FLOOR, NEW YORK NY, 10007. The biotechnology company can be reached via phone at 646-975-2500 or via email at [email protected]
MarketBeat Community Rating for Progenics Pharmaceuticals (PGNX)MarketBeat's community ratings are surveys of what our community members think about Progenics Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Progenics Pharmaceuticals (NASDAQ:PGNX) Analysts' Consensus Rating (How are Consensus Ratings Calculated?)
MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
|Today||30 Days Ago||90 Days Ago||180 Days Ago|
|Consensus Rating: ||Buy||Buy||Buy||Buy|
|Consensus Rating Score: ||3.25||3.25||3.25||3.17|
|Ratings Breakdown: ||0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
3 Buy Rating(s)
1 Strong Buy Rating(s)
|0 Sell Rating(s)|
0 Hold Rating(s)
5 Buy Rating(s)
1 Strong Buy Rating(s)
|Consensus Price Target: ||$13.75||$13.75||$13.75||$12.83|
|Price Target Upside: ||82.36% upside||123.58% upside||122.13% upside||104.68% upside|
Progenics Pharmaceuticals (NASDAQ:PGNX) Consensus Price Target History
Progenics Pharmaceuticals (NASDAQ:PGNX) Analyst Ratings History
(Data available from 3/24/2016 forward)
Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings History and Estimates Chart
Progenics Pharmaceuticals (NASDAQ PGNX) Earnings History by Quarter
(Earnings results data provided by Zacks Investment Research)
|Date||Quarter||Consensus Estimate||Actual EPS||Revenue Estimate||Actual Revenue||Release Link||Conference Call||Details|
|3/8/2018||Q4 2017||($0.21)||($0.21)||$3.18 million||$3.90 million||View||N/A|
|11/2/2017||Q3 2017||($0.24)||($0.22)||$3.58 million||$2.70 million||View||N/A|
|8/9/2017||Q2 2017||($0.20)||($0.24)||$3.34 million||$2.77 million||View||Listen|
|5/4/2017||Q1 2017||($0.16)||($0.23)||$4.50 million||$2.40 million||View||Listen|
|3/9/2017||Q4 2016||($0.20)||($0.10)||$4.43 million||$4.65 million||View||Listen|
|11/7/2016||Q316||$0.55||$0.52||$52.90 million||$53.90 million||View||Listen|
|8/4/2016||Q216||($0.13)||($0.08)||$6.33 million||$8.50 million||View||N/A|
|5/5/2016||Q116||($0.13)||($0.18)||$3.27 million||$2.50 million||View||Listen|
|3/11/2016||Q415||($0.14)||($0.10)||$2.25 million||$5.10 million||View||Listen|
|11/9/2015||Q315||($0.13)||($0.14)||$2.35 million||$1.40 million||View||Listen|
|8/6/2015||Q215||($0.15)||($0.17)||$1.63 million||$1.90 million||View||Listen|
|5/6/2015||Q115||($0.16)||($0.15)||$1.30 million||$0.25 million||View||N/A|
|3/16/2015||Q414||($0.13)||($0.18)||$2.87 million||($0.57) million||View||N/A|
|11/7/2014||Q314||($0.16)||$0.51||$2.50 million||$41.66 million||View||N/A|
|8/8/2014||Q214||($0.14)||($0.17)||$2.83 million||$1.50 million||View||Listen|
|5/9/2014||Q114||($0.15)||($0.15)||$2.88 million||$1.80 million||View||N/A|
|3/13/2014||Q4||($0.19)||($0.14)||$1.48 million||$3.00 million||View||Listen|
|3/3/2014||Q4 2013||($0.19)||($0.14)||$1.74 million||$2.97 million||View||N/A|
|11/11/2013||Q313||($0.22)||($0.17)||$2.00 million||$0.90 million||View||N/A|
|8/9/2013||Q2 2013||($0.24)||($0.24)||$1.86 million||$1.80 million||View||N/A|
|5/10/2013||Q1 2013||($0.19)||($0.22)||$1.71 million||$2.23 million||View||N/A|
|3/15/2013||Q4 2012||($0.31)||($0.01)||$1.16 million||$8.87 million||View||N/A|
|11/8/2012||Q312||($0.30)||($0.33)||$2.52 million||$1.10 million||View||N/A|
Progenics Pharmaceuticals (NASDAQ:PGNX) Earnings Estimates
2018 EPS Consensus Estimate: ($0.83)
(Earnings estimates data provided by Zacks Investment Research)
|Quarter||Number of Estimates||Low Estimate||High Estimate||Average Estimate|
Dividend History for Progenics Pharmaceuticals (NASDAQ:PGNX)
No dividend announcements for this company have been tracked by MarketBeat.com
Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 3.63%
Institutional Ownership Percentage: 83.67%
Progenics Pharmaceuticals (NASDAQ PGNX) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|2/15/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||602,600||$9.66||$5,821,116.00|| |
|2/9/2017||Healthcare Master Fun Broadfin||Major Shareholder||Sell||351,300||$9.71||$3,411,123.00|| |
|6/11/2015||Robert J Israel||EVP||Sell||2,000||$6.83||$13,660.00|| |
|3/13/2015||Robert J Israel||EVP||Sell||3,000||$7.00||$21,000.00|| |
|3/11/2015||Robert J Israel||EVP||Sell||2,000||$6.83||$13,660.00|| |
|3/3/2015||Robert J Israel||EVP||Sell||5,000||$6.49||$32,450.00|| |
|1/12/2015||Robert J Israel||EVP||Sell||2,000||$7.06||$14,120.00|| |
|12/11/2014||Robert J Israel||EVP||Sell||3,000||$7.07||$21,210.00|| |
|11/21/2014||Robert J Israel||EVP||Sell||9,000||$7.00||$63,000.00|| |
|11/13/2014||Robert J Israel||EVP||Sell||10,000||$6.83||$68,300.00|| |
|11/11/2014||Robert J Israel||EVP||Sell||5,000||$6.53||$32,650.00|| |
|7/21/2014||Healthcare Master Fun Broadfin||Major Shareholder||Buy||1,625,436||$4.60||$7,477,005.60|| |
|7/18/2014||Healthcare Master Fun Broadfin||Major Shareholder||Buy||388,200||$4.73||$1,836,186.00|| |
|7/17/2014||Healthcare Master Fun Broadfin||Major Shareholder||Buy||436,884||$4.48||$1,957,240.32|| |
|7/16/2014||Healthcare Master Fun Broadfin||Major Shareholder||Buy||411,693||$4.48||$1,844,384.64|| |
|7/18/2013||Robert J Israel||VP||Sell||5,000||$6.33||$31,650.00|| |
|2/27/2013||Mark Robert Baker||CEO||Buy||1,262||$2.72||$3,432.64|| |
|1/22/2013||Mark Robert Baker||CEO||Buy||1,215||$2.82||$3,426.30|| |
|12/26/2012||Mark Robert Baker||CEO||Buy||1,142||$3.01||$3,437.42|| |
|11/28/2012||Mark Robert Baker||CEO||Buy||1,607||$2.13||$3,422.91|| |
|11/19/2012||Mark Robert Baker||CEO||Buy||11,800||$1.96||$23,128.00|| |
|11/16/2012||Mark Robert Baker||CEO||Buy||49,793||$1.82||$90,623.26|| |
|11/15/2012||Mark Robert Baker||CEO||Buy||48,833||$1.69||$82,527.77|| |
|10/24/2012||Mark Robert Baker||CEO||Buy||1,162||$2.96||$3,439.52|| |
|9/26/2012||Mark Robert Baker||CEO||Buy||1,036||$3.32||$3,439.52|| |
Progenics Pharmaceuticals (NASDAQ PGNX) News Headlines
|3 Things In Biotech, March 23: Booking 3 Pieces Of Bad News|
seekingalpha.com - March 24 at 5:12 PM
|Progenics Pharmaceuticals (PGNX) Rating Increased to Buy at BidaskClub|
www.americanbankingnews.com - March 24 at 3:52 PM
|Is the FDA Expecting More Problems for Progenics? - 24/7 Wall St.|
247wallst.com - March 24 at 8:19 AM
|Progenics Pharmaceuticals (PGNX) Given a $15.00 Price Target at Cantor Fitzgerald|
www.americanbankingnews.com - March 23 at 6:06 PM
|Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Expected To Breakeven|
finance.yahoo.com - March 23 at 9:03 AM
|Progenics Pharma (PGNX) Announces Three-Month Extension of PDUFA Date for AZEDRA - StreetInsider.com|
www.streetinsider.com - March 22 at 4:53 PM
|Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131) - GlobeNewswire (press release)|
globenewswire.com - March 22 at 4:53 PM
|Progenics Pharmaceuticals Announces Three-Month Extension of PDUFA Date for AZEDRA® (iobenguane I 131)|
finance.yahoo.com - March 22 at 4:53 PM
|5 Big Biotech Stocks to Buy Under $10 - Investorplace.com|
investorplace.com - March 20 at 4:49 PM
|Progenics Pharmaceuticals Announces Presentation of AZEDRA ... - Nasdaq|
www.nasdaq.com - March 20 at 4:49 PM
|Progenics Pharmaceuticals, Upcoming PDUFA Date, Analysts Target Price, Pipeline Review|
finance.yahoo.com - March 20 at 9:14 AM
|Progenics Pharmaceuticals to Present at the 17th Annual Needham Healthcare Conference|
finance.yahoo.com - March 20 at 9:14 AM
|Equities Analysts Set Expectations for Progenics Pharmaceuticals, Inc.'s FY2018 Earnings (PGNX)|
www.americanbankingnews.com - March 14 at 9:50 AM
|Progenics Pharmaceuticals (PGNX) Downgraded by Zacks Investment Research|
www.americanbankingnews.com - March 14 at 6:48 AM
|Our Post-Earnings Take On Progenics Pharmaceuticals - Seeking Alpha|
seekingalpha.com - March 13 at 4:59 PM
|Progenics Pharmaceuticals, Inc. (PGNX) to Post Q1 2018 Earnings of ($0.23) Per Share, Jefferies Group Forecasts|
www.americanbankingnews.com - March 12 at 1:52 AM
|Progenics Pharmaceuticals (PGNX) Upgraded at BidaskClub|
www.americanbankingnews.com - March 10 at 11:34 PM
|Progenics Pharmaceuticals (PGNX) Posts Quarterly Earnings Results, Beats Expectations By $0.19 EPS|
www.americanbankingnews.com - March 8 at 2:45 PM
|Progenics Pharmaceuticals Announces Fourth Quarter and Full-Year 2017 Financial Results and Business Update|
finance.yahoo.com - March 8 at 10:31 AM
|Progenics Pharmaceuticals reports Q4 results|
seekingalpha.com - March 8 at 8:15 AM
|Progenics Pharmaceuticals Inc (NASDAQ:PGNX) Is Trading At A 41.88% Discount To Its Intrinsic Value|
finance.yahoo.com - March 5 at 4:49 PM
|Investors Purchase Large Volume of Put Options on Progenics Pharmaceuticals (PGNX)|
www.americanbankingnews.com - March 2 at 7:30 AM
|Traders Buy High Volume of Call Options on Progenics Pharmaceuticals (PGNX)|
www.americanbankingnews.com - March 2 at 7:28 AM
|Fuller & Thaler Asset Management Inc. Sells 106,400 Shares of Progenics Pharmaceuticals, Inc. (PGNX)|
www.americanbankingnews.com - March 1 at 10:50 AM
|Progenics Pharmaceuticals Sets Fourth Quarter and Year-End 2017 Financial Results Call for March 8|
finance.yahoo.com - March 1 at 9:25 AM
|Carillon Tower Advisers Inc. Invests $21.79 Million in Progenics Pharmaceuticals, Inc. (PGNX)|
www.americanbankingnews.com - March 1 at 5:38 AM
|Progenics Pharmaceuticals, Inc. (PGNX) Shares Sold by Royce & Associates LP|
www.americanbankingnews.com - February 28 at 9:42 AM
|Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Brokerages|
www.americanbankingnews.com - February 28 at 5:36 AM
|Progenics Pharmaceuticals (PGNX) Set to Announce Quarterly Earnings on Wednesday|
www.americanbankingnews.com - February 28 at 1:40 AM
|KBC Group NV Has $1.30 Million Stake in Progenics Pharmaceuticals, Inc. (PGNX)|
www.americanbankingnews.com - February 25 at 6:40 AM
|Progenics Pharmaceuticals (PGNX) Presents At RBC Capital Markets Global Healthcare Conference - Slideshow|
seekingalpha.com - February 23 at 4:42 PM
|Progenics Pharmaceuticals (PGNX) Lifted to Hold at BidaskClub|
www.americanbankingnews.com - February 18 at 1:00 PM
|Progenics Pharmaceuticals to Present at the 2018 RBC Capital Markets Global Healthcare Conference|
finance.yahoo.com - February 15 at 4:46 PM
|Progenics Pharmaceuticals Sees Unusually High Options Volume (PGNX)|
www.americanbankingnews.com - February 14 at 5:50 PM
|Progenics Pharmaceuticals (PGNX) Presents At BIO CEO & Investor Conference - Slideshow|
seekingalpha.com - February 14 at 3:27 PM
|Progenics Pharmaceuticals to Present at the 2018 BIO CEO & Investor Conference|
finance.yahoo.com - February 5 at 3:24 PM
|Progenics Pharmaceuticals (PGNX) Stock Rating Lowered by BidaskClub|
www.americanbankingnews.com - February 3 at 11:58 AM
|Progenics Pharmaceuticals, Inc. (PGNX) Given Consensus Recommendation of "Hold" by Brokerages|
www.americanbankingnews.com - February 3 at 5:28 AM
|Progenics Pharma (PGNX) Announces Presentation of AZEDRA Biochemical Tumor Marker Data at ENDO - StreetInsider.com|
www.streetinsider.com - February 2 at 6:28 AM
|Progenics Pharmaceuticals Announces Presentation of AZEDRA® (iobenguane I 131) Biochemical Tumor Marker Data at the 2018 Endocrine Society (ENDO) Annual Meeting|
feeds.benzinga.com - February 1 at 5:13 PM
|Quotidian Technical Highlights on Selected Biotech Stocks -- PDL BioPharma, Progenics Pharma, Pain Therapeutics ... - PR Newswire (press release)|
www.prnewswire.com - January 20 at 4:14 PM
|Progenics Pharmaceuticals: An Underappreciated Company You Can't Afford To Ignore - Seeking Alpha|
seekingalpha.com - January 20 at 4:14 PM
|Cantor Fitzgerald Reiterates "Buy" Rating for Progenics Pharmaceuticals (PGNX)|
www.americanbankingnews.com - January 18 at 1:50 PM
|Progenics Pharmaceuticals, Inc. (PGNX) Receives Average Rating of "Buy" from Analysts|
www.americanbankingnews.com - January 9 at 8:12 AM
|Progenics Pharmaceuticals (PGNX) Lowered to Hold at Zacks Investment Research|
www.americanbankingnews.com - January 6 at 7:02 AM
|Traders Buy High Volume of Progenics Pharmaceuticals Put Options (PGNX)|
www.americanbankingnews.com - January 5 at 2:10 AM
|Your Daily Pharma Scoop: Progenics Azerda Update, Atara Gets FDA Clearance For Phase 3 Trial, Avadel Provides ... - Seeking Alpha|
seekingalpha.com - January 2 at 10:09 AM
|Progenics Pharma (PGNX) Reports Completion of Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404 - StreetInsider.com|
www.streetinsider.com - January 2 at 10:09 AM
|Progenics Pharmaceuticals Completes Enrollment in Phase 3 Study of PSMA-Targeted Imaging Agent 1404|
finance.yahoo.com - January 2 at 10:09 AM
|Progenics Pharmaceuticals Target of Unusually High Options Trading (PGNX)|
www.americanbankingnews.com - January 1 at 2:28 AM
Progenics Pharmaceuticals (NASDAQ:PGNX) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Progenics Pharmaceuticals (NASDAQ:PGNX) Income Statement, Balance Sheet and Cash Flow Statement
Progenics Pharmaceuticals (NASDAQ PGNX) Stock Chart for Saturday, March, 24, 2018